MARCH 23RD AND SAVE UP TO €400

24th-26th April, 2018 | Amsterdam, NL

www.neoantigen-europe.com

European NEOANTIGEN Summit2018

Supercharging Personalised Cancer Vaccines & Immunotherapies



Advancing Neoantigen Identification, Optimising Prediction Strategies and Accelerating the Manufacture of Neoantigen-based Targeted Therapies

Expert Speakers Including:

Jim Johnston
Executive Director, Inflammation
Amgen

Martin Löwer
Head of Bioinformatics
TRON

Heinz Lubenau
COO
VAXIMM GmbH

Matthias Miller
Senior Project Manager
BioNTech

Agnete Fredriksen
CSO
Vaccibody

Sebastiano Battaglia
Assistant Professor of Oncology, Centre of Immunotherapy
Roswell Park Cancer Centre

Partners: CAPRION · Personalis · ALMAC · OncoImmunity · BACHEM

Tel: +44 203 141 8700 | Neoantigens in Immunotherapy

hansonwade

Join the Rapidly Accelerating Neoantigen Movement

Enhancing the specificity and personalised nature of cancer vaccines and cell-based immunotherapies through the use of individualised, immunogenic neoantigens

The **2nd Annual European Neoantigen Summit** is dedicated to supercharging tumour targeting through the identification, prediction and utilisation of the most cutting-edge neoantigen strategies.

Join the leaders across pharma and biotech to discuss how the current in silico methods for identifying neoantigens will spur on the next generation of personalised cancer immunotherapies.

Build a commercial roadmap for the manufacture of personalised therapies at scale and navigate the regulatory minefield to understand how to develop and deliver clinical trials for regulatory approval.

Meet the experts in the field in Amsterdam to analyse the approaches being used to measure peptide binders of MHC molecules to improve algorithm accuracy, providing the strongest foundation on which to advance your drug development programme.

Ensure that immunogenic neoantigens become the rule rather than the exception, bringing personalised cancer immunotherapies to new heights.

What Hanson Wade's attendees have said about our meetings

> This meeting was the most comprehensive survey of the emerging field of neoantigen-based therapeutics. This was a well organized conference with excellent speakers
>
> Argos Therapeutics

> This meeting was a very efficient way to meet the companies and hear the main players in the field discuss the technologies and the clinical endeavors to use neoantigens in various types of immunotherapy. The meeting was well organized
>
> Medigene

Manoeuvre Through Neoantigen Therapeutic Development

1. **Advancing Prediction Strategies:** Dismantle and analyse the key elements of successful neoantigen prediction, increasing the hit-rate and streamlining the process



2. **Manufacturing Personalised Immunotherapies:** Ensure operational efficiency when scaling up neoantigen personalised therapies to meet patient demand

3. **Guaranteeing Immunogenicity:** Examining the most up-to-date methods for interrogating neoantigens to ensure an immune response and by extension an effective therapeutic



4. **Reinvigorating Cancer Vaccines:** Harnessing neoantigens to ensure your vaccine approach produces strong clinical efficacy



5. **Mapping the Regulatory Landscape:** Understand the regulatory pathways required for clinical trials and approvals of truly individualised patient therapies

Your Expert Speakers

Andrea van Elsas
CSO
Aduro Europe

Jim Johnston
Executive Director, Inflammation
Amgen

Hyewon Phee
Senior Scientist & Project Manager, Inflammation
Amgen

Stephen Johnston
Director, Centre for Innovations in Medicine, Biodesign Institute
Arizona State University

Matthias Miller
Senior Project Manager
BioNTech

Eustache Paramithiotis
Vice-President, Discovery
Caprion Biosciences

Morten Nielsen
Professor, Group leader Immunoinformatics and Machine-Learning, Center for Biological Sequence Analysis
The Technical University of Denmark

Suchit Jhunjhunwala
Scientist, Bioinformatics & Computational Biology
Genentech

Toni Weinschenk
Founder & CTO
Immatics Biologics

Nadine Defranoux
Program Manager
Parker Institute for Cancer Immunotherapy

Personalis

Oncoimmunity

Sebastiano Battaglia
Assistant Professor of Oncology, Centre of Immunotherapy
Roswell Park Cancer Centre

Kaïdre Bendjama
Personalized Vaccination Project Lead
Transgene S.A.

Martin Löwer
Head of Bioinformatics
TRON

Michal Bassani-Sternberg
Director, Immunopeptidomics Unit, Department of Oncology
UNIL/CHUV

Alexandre Harari
Associate Director, Centre of Experimental Therapeutics
UNIL/CHUV

Agnete Fredriksen
CSO
Vaccibody

Heinz Lubenau
COO
VAXIMM GmbH

"The Neoantigen Summit was a great meeting which enabled me to learn a lot whilst making some great connections! This is a fast-moving field and meetings like this are incredibly important to keep the people involved moving forward. Very well organised conference. Very pleased!"
Meditope Biosciences

Conference Day One | Wednesday 25th April 2018

	7.30	**Breakfast & Registration**
	8.30	**Chairman's Opening Remarks**

Optimising the Identification and Prediction of Neoantigens

Martin Löwer Head of Bioinformatics **TRON**	8.45	**Overcoming Neoantigen Prediction Challenges in Clinical Application** • Overview of factors for neoantigen prediction (Mutation detection, antigen presentation, antigen recognition) • Establishing reliable mutation detection • Strategies for neoantigen selection • Mitigating the risks in selection processes • Emerging factors
Morten Nielsen Professor, Group leader Immunoinformatics and Machine-Learning, Center for Biological Sequence Analysis **The Technical University of Denmark**	9.15	**Advances in the Field of In-silico Methods for the Identification of Neoepitopes** • Due to the high selectivity of the MHC molecules, major efforts have been dedicated to characterize their binding specificity and several in-silico methods have been developed to predict this event • Overview of the recent advances in prediction methods for rational epitope discovery • Show how the use of MS peptidomics data in can substantially enhance our ability to predict both MHC class I and MHC class II ligands and epitopes, and how the processing signal contained within MHC class II MS peptidome data can be used to improve predictive accuracy • Demonstrate how peptide similarity to self serves as an important factor for predicting peptide immunogenicity • Discuss how T cell receptor data can be used to refine our understanding of peptide immunogenicity, and present results suggesting that the cognate target of a T cell can be predicted from the sequence of T cell receptor • Discussion on limitations of the state-of-the-art tools, and suggest solutions for how to move the field forward dealing with these limitations
Oncoimmunity	9.45	**An Integrated Machine-Learning Approach to Improve the Prediction of Clinically Relevant Neoantigens** • Current neoantigen discovery algorithms are not optimal to predict presentation to the cell surface • Here, we outline a high-performing machine learning approach, trained on mass-spectrometry data, that predicts naturally processed and presented antigens • The predictor is integrated with several immune parameters, such as HLA binding, in a deep learning layer to predict bone fide neoantigens • We illustrate its application to significantly improve the identification of neoantigen targets for personalized cancer immunotherapy
	10.15	**Morning Refreshments & Speed Networking**
Michal Bassani-Sternberg Director, Immunopeptidomics Unit, Center of Experimental Therapeutics **Department of Oncology UNIL/ CHUV**	11.15	**Immunopeptidomics: Accelerating the Development of Personalised Cancer Immunotherapy - How can we Improve Identification and Prioritisation of Neoantigens with MS Based Immunopeptidomics?** • We have developed a new high-throughput, reproducible and sensitive immunopeptidomics platform that improves recovery and overall sensitivity for direct mass spectrometry based identification of neoantigens • We have showed that incorporation of deconvoluted immunopeptidomics data in ligand prediction algorithms can improve their performance • We have reported that by taking advantage of co-occurring HLA-I alleles one can rapidly and accurately identify HLA-I binding motifs and map them to their corresponding alleles without any a priori knowledge of HLA-I binding specificity. This novel and scalable approach uncovers new motifs for several alleles that had no known ligands • In addition to providing huge training data to improve the HLA binding prediction, immunopeptidomics also captures other aspects of the natural in vivo presentation that significantly improve prediction of clinically relevant neoantigens


Jim Johnston
Executive Director
Amgen


Martin Löwer
Bioinformatics
TRON


Michal Bassani-Sternberg
Immunopeptidomics
UNIL/CHUV


Nadine Defranoux
Program Manager
Parker Institute for Cancer Immunotherapy

11.45 ***Panel:* Determining Best Practices for Neoantigen Prediction**
- How can you best predict the clinical relevance on your neoantigens?
- Use of in silico methods to enable the intelligent selection of mutations likely to result in high-affinity epitopes that bind to MHC molecules
- Analysis of immunoinformatics and computational tools for neoantigen prediction
- How can we harness machine learning to improve the efficiency of how neoantigens are validated?

12.45 **Lunch & Networking**


Eustache Paramithiotis
Vice-President, Discovery
Caprion Biosciences

1.45 **Characterisation of Novel Cancer and Neoepitopes**
- Primary cancer data
- Metastatic cancer
- Normal tissue expression
- Functional characterisation

Guaranteeing Immunogenicity


Alexandre Harari
Professor
CHUV

2.15 **Sensitive Identification and Functional Profiling of Neoepitopespecific T Cells**
- The frequency of neoepitope reactive T cells is decreasing during TIL expansion but this can be circumvented in order to enrich TILs in neoepitope-specific T cells
- The neoepitope repertoire is discordant between circulating and tumor-infiltrating lymphocytes
- Neoepitope-specific T cells are functionally heterogeneous
- High-throughput strategies to validate neoepitopes and to isolate neoepitope-specific T cells are needed to bring mutanome-based immunotherapy into the clinic


Hyewon Phee
Senior Scientist & Project Manager, Inflammation
Amgen

2.30 **Immunogenicity of Neoantigen Cancer Vaccines**
- Specific content awaiting internal approval

3.15 **Afternoon Refreshments & Networking**

> "This was my first Hanson Wade meeting and I am very pleased with how focused the meeting was and the relevance of the speakers and attendees."
> OncoImmunity

Sebastiano Battaglia
Assistant Professor of Oncology, Centre of Immunotherapy
Roswell Park Cancer Centre

3.45 Optimising the Neoantigenic Landscape in Low Mutational Burden Tumours for Optimal T Cells Response

- Assessing the multidimensional challenge of identifying reactive neoantigens
- As sequence analysis tools and prediction algorithms promise optimal neoantigen calls, T cells status and tumour microenvironment can limit the number of truly reactive neoantigens in cancer patients
- Variant identification is a key limiting factor
- Neoantigen identification can be optimised by ranking epitopes based on combined prediction values
- Magnitude of TILs infiltration does not translate into optimal patient's response
- TCR repertoire dictates response to neoantigen
- Neoantigens from driver mutations could also be exploited for augmented anti-tumor response

Suchit Jhunjhunwala
Scientist, Bioinformatics & Computational Biology
Genentech

4.15 Determinants of Immunogenicity of Neoantigens

- Overview of personalized identification of neoantigens using mouse models
- Mouse vaccination studies to identify immunogenic neoantigens
- Identification of physical-chemical properties of neoepitope candidates that are enriched in immunogenic neoepitopes
- Application of mass spectrometry to train bioinformatics methods to further enrich for neoantigens
- Reproducibility of bioinformatics methods to enrich for neoantigens between mouse and human studies

Creating the Appropriate Clinical Trials for Neoantigen Based Therapies

Personalis

4.45 Shifting the Cancer Vaccine Development Paradigm: NGS Best Practices for Neoantigen Detection & Clinical Trial Implementation

- NGS-guided analysis of DNA and RNA for sensitive neoantigen identification shows great promise, yet standard approaches and conventional assays suffer from limitations including gaps in coverage, narrow genomic footprint, and limited validation
- Personalis leverages its proprietary Accuracy and Content Enhanced (ACETM) technology platform, ImmunoID, to improve cancer exome and transcriptome sequencing. This platform is developed for use with our neoantigen prediction analysis pipeline
- This presentation will discuss the technical characteristics of this enhanced assay with an overview of the robust analytical validation performed
- A review of the need for designing rapid, patient-centric processes for vaccine clinical trials will be outlined
- Personalis' unique technology contributes to advancing genome-guided medicine for truly personalised cancer care

5.15 Chairman's Closing Remarks

5.30 Close of Day 1

"The best conference I have found that focuses specifically on neoantigens"

ACT Genomics

Conference Day Two | Thursday 26th April, 2018

8.00 **Breakfast & Networking**

9.00 **Chairman's Opening Remarks**

Advancing Cell & Vaccine-based Therapies

Matthias Miller
Senior Project Manager
BioNTech

9.15 **Reinvigorating Cancer Vaccines with Neoantigen Targeting Individualised mRNA-based Vaccines for the Treatment of Cancer**

- Harnessing mutation-derived neoantigens for the manufacture of RNA-based vaccines for the treatment of cancer
- Personalised vaccines against cancer (IVAC®)
- Clinical development of IVAC® MUTANOME

Andrea van Elsas
CSO
Aduro Europe

9.45 **Live-Attenuated Double Deleted Listeria Monocytogenes (pLADD) Immunotherapy Targeting MSS CRC**

- Aduro's Live attenuated Listeria (LADD) engages the innate immune response and remodels the tumor microenvironment in both mouse cancer models and in patients
- Proprietary methods have been established for the rapid construction of pLADD strains by site-specific placement of neoantigen expression cassette on bacterial chromosome expressing at least 25 epitopes together with immunoproteosome processing motifs
- pLADD is being evaluated in advanced liver metastatic MSS colorectal cancer (CRC), a malignancy of large unmedical need in which immune checkpoint inhibitors have poor efficacy as single agents
- MSS CRC has a medium mutational burden of ~10 to 100 mutations/tumour cell, simplifying identification and selection of immunogenic neo-epitopes
- Have developed a streamlined needle-to-needle workflow from biopsy to treatment of 12 weeks
- Presentation of data from a Phase 1 clinical trial initiated at Stanford in collaboration with George Fisher, MD (clinical PI) and Hanlee Ji, MD, PhD (neo-antigen prediction)

10.15 **Morning Refreshments & Networking**

Toni Weinschenk
Founder & CTO
Immatics Biologics

10.45 **Personalised Onco-Immunotherapy: *in vivo* and *ex vivo* Vaccination Trials**

- GAPVAC – Glioma Actively Personalized Vaccine Consortium: A personalized peptide vaccination trial
- ACTolog®, a personalised multi-target Adoptive Cellular Therapy (ACT)
- XPRESIDENT®: Quantitative HLA ligandomes in cancer and normal tissues
- Targets for bispecific T-cell recruiters

Heinz Lubenau
COO
VAXIMM GmbH

11.15 **Fast and Cost-Effective Oral Delivery Technology of Personalised T-Cell Vaccines Based on a Live Attenuated Bacteria Platform**

- The platform is based on the live attenuated bacterial vaccine strain Ty21, which has been administered to millions of people as a prophylactic vaccine to temporarily protect them from typhoid fever. This strain has been proven to be very safe and well tolerated. All immunotherapies resulting from this platform are taken orally by the patient
- The oral bacterial technology enables delivery to the most immunocompetent organ of the body, targeting the lymphatic tissue of the gut, and has been shown to generate robust T-cell responses against many different antigens in animals and humans in first clinical studies
- The low therapeutic doses required for specific T-cell activation make this approach suitable for continuous dosing (prime & boost administrations, without raising anti-carrier immunity) and provides another safety margin for carrier-related toxicity
- The platform is suitable for addressing multiple targets, full-length proteins as well as small peptides including neo-epitopes, with one treatment and can be combined with additional immune therapies. Another major advantage of this approach is the high modularity, and the low cost and robustness of the production process
- Different prediction strategies have been established to identify tumor-specific mutations, which lead to neoantigens or neoepitopes. Targeting neoantigens by generating specific cytotoxic T-cells is becoming a major factor in the development of clinical immunotherapies against cancer. Our platform technology allows for a fast generation and delivery of personalised T-cell vaccines for the treatment of cancer
- In preclinical studies the technical proof of concept and the ability to raise robust epitope-specific immune responses after administration of polyepitope constructs have been shown

Matthias Miller
Senior Project Manager
BioNTech

Andrea van Elsas
CSO
Aduro Europe

Toni Weinschenk
Founder & CTO
Immatics Biologics

11.45 ***Panel:* Maximising the Potential of Neoantigen-based Targeting for Cancer Vaccines**

- How can we harness combination approaches for successful cancer vaccination?
- Lessons learned from examining neoantigen-based cancer vaccine clinical trials to date
- What level of dosage is required?
- Can the benefit of multiple-neoantigen therapies justify the cost, or is it possible to bring the cost down significantly?
- Should we be selecting naturally occurring T cells or TCR gene engineered cells?
- How can we rapidly identify TCRs against neoantigens that could be used to generate personalised cell therapies?

12.30 **Lunch & Networking**

Stephen Johnston
Director, Centre for Innovations in Medicine, Biodesign Institute
Arizona State University

1.30 **A New Source of Highly Immunogenic Neoepitopes for Cancer Vaccines**

- MisTranslation through microsatellites and mis-splicing produce 100x more neoantigens than DNA mutations
- Frameshifts (FS) produced by MisTranslation and Splicing are highly immunogenic
- These FS are protective in mouse models
- People and dogs with cancer raise immune responses to these FS
- This FS reactivity can be detected using a peptide array
- In a mouse model this array-based system can be used to rapidly create a personal vaccine that shows protection

Kaïdre Bendjama
Personalized Vaccination Project Lead
Transgene S.A.

2.00 **Redirecting Anti-Viral Immunity to Fight Cancer with Tumor Specific Neoantigens**

- The immune system is naturally sensitive and responsive to viral infections; viral vectors thus represent exquisite platforms for immune intervention and presentation of tumor antigens
- Transgene's viral platforms redirect the anti-viral innate and specific immunity to fight tumor cells, mostly by boosting the selection and amplification of specific T cells, and by a diversification mechanism called epitope spreading
- Our viral based anti-cancer vaccines had been administered safely to hundreds of patients and have been shown to effectively triggers clinically relevant specific immune responses
- A proprietary workflow has been developed for the construction and quality control of a pharmaceutical grade neoantigen vaccines within weeks of the generation of sequence data
- The large genetic payload is suitable to neoantigens resulting from missense or frameshift mutations, and/or large active molecules such as antibodies or cytokines
- Preclinical data on vector immunogenicity, and envisioned clinical translation plans for the neoantigen viral vaccine will be presented

Overcoming Regulation and Manufacturing Challenges for Personalised Therapies

Agnete Fredriksen
CSO
Vaccibody

2.30 **Individualised Cancer Neoantigen Vaccines: How can we Make it a Viable Product?**

- What is the rationale to pursue development of individualised cancer vaccines?
- How can we customise and manufacture one vaccine per patient at reasonable cost?
- How does the therapeutic modality affect the immunogenicity of individual neoepitopes?
- How do we design a clinical trial for private cancer neoantigen based vaccines?

Matthias Miller
Senior Project Manager
BioNTech

Agnete Fredriksen
CSO
Vaccibody

Heinz Lubenau
COO
VAXIMM GmbH

3.00 ***Panel:* Advancing Manufacturing Practices for Personalized Cancer Vaccines**

- How do manufacturing priorities change between key modalities?
- How can you ensure you neoantigen based therapy is affordable?
- Examining cost of materials and sourcing
- Where can the key benefits arise from the implement the automation of manual steps?
- Ensuring operational efficiency
- How fast can you define neoantigens, manufacture and provide them in a formulation for patient treatment?
- Best practice takeaways

3.45 **Chairman's Closing Remark**

4.00 **Close of Summit**

Post-Conference Workshop Day | Tuesday 24th April 2018

Workshop A

A Leap Forward in Neoantigen Identification and Prediction

9:00am – 12:00pm

Identification and prediction of neoantigens forms the basis of effective individualised therapies in this space. The implementation and constant development of bioinformatics approaches underpins this process, and must interrogate a number of key areas to guarantee effectiveness:

- Prediction of mutated peptides and peptide immunogenicity
- MHC class I and MHC class II ligands and epitopes
- Rational epitope discovery
- Analysing data from matched tumours and normal samples
- Selection of expressed peptides by integrating HLA typing

This workshop provides you with a comprehensive view of all the techniques and technologies currently being used to develop neoantigen-based therapies. Leave this session with the information you need to ensure you are using the most up to date, efficient, accurate and reliable processes.

Workshop Leader

Morten Nielsen, Professor, Group Leader Immunoinformatics and Machine-Learning, Center for Biological Sequence Analysis, **The Technical University of Denmark**

The core of Morten Nielsen's research deals with the development of novel and advanced data-driven prediction methods for pattern recognition in biological systems. Morten Nielsen is a pioneer in the field of immunological bioinformatics and a key inventor of several state-of- the-art methods for T and B cell epitope discovery. He has been a partner in several large epitope discovery grants and has published numerous articles and book chapters within the fields of immunology, immunological bioinformatics and neural networks.

Workshop B

Optimizing Manufacturing Processes for Individualised Cancer Vaccines

1:00pm – 4:00pm

The manufacture of individualised therapies presents a huge logistical challenge and requires a complete overhaul of current systems. This session provides a detailed insight into upscaling the manufacture of individualised cancer vaccine to meet market demand:

- Key considerations when manifesting therapies centred around each of the prevalent modalities
- Manufacturing individualised therapies at scale
- What steps can be taken to ensure that your neoantigen based therapy is affordable?
- Cost-effective methods for sourcing key materials
- Strategy alterations for combination therapies

This workshop highlights the key areas of manufacturing for neoantigen vaccines. Leave the session with actionable insights for the planning, implementation and maintenance of manufacturing strategies for personalised cancer vaccines.

Workshop Leaders

Agnete Fredriksen
CSO
Vaccibody

Matthias Miller
Senior Project Manager
BioNTech

Andrea van Elsas
CSO
Aduro Biotech

SPONSOR

ABOUT PARTNERSHIP

The European Neoantigen Summit 2018 is leading end-to-end meeting dedicated to supercharging the immunotherapies field **where VPs, Directors and C-Level Executives** are coming to search for the right partners.

While the promise is huge, these therapies remain a new approach poised for an explosive stage of development. The ***European Neoantigens Summit*** enables the field ***to establish long term partnerships to secure future success.***

Network with new clients and cement existing relationships via our speed networking, **personal introductions** and our multiple industry-wide touch points.

Several opportunities exist to **educate the industry on your product or service** including speaking positions, exhibiting and hosting evening receptions.

Oncoimmunity, Industry Development Partner

OncoImmunity is a bioinformatics company offering proprietary machine-learning based software to address the key knowledge gaps in the prediction of bone fide immunogenic neoantigens for personalized cancer immunotherapy. OncoImmunity is dedicated to develop software solutions that facilitate effective patient selection for cancer immunotherapy, and identify optimal neoantigen targets for truly personalised cancer vaccines & cell therapies in clinically actionable time-frame.

Personalis, Programme Partner

Personalis, Inc. provides genomic solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. Our patented ACE Technology improves every step in the sequencing process, from nucleic acid extraction, to sequencing, to data analytics. This delivers augmented coverage of difficult-to-sequence genomic regions that are missed with conventional sequencing techniques. This comprehensive approach provides data of the highest quality to enable the rational design and development of effective cancer immunotherapies.

www.personalis.com

Bachem, Event Partner

Bachem provides a full range of services to the pharma and biotech industries. It specializes in the development of innovative, efficient manufacturing processes and the reliable production of peptide-based active pharmaceutical ingredients. The group has a global reach with more experience and know-how than any other company in the industry. Towards its customers, Bachem shows total commitment to quality, innovation and partnership. Bachem. Pioneering Partner for Peptides

www.bachem.com

Provepharm Life Solutions, Event Partner

We are Provepharm Life Solutions. We are building a new powerhouse for Research Services, Manufacturing Services and Speciality Care, dedicated to a new era of discovery.
We are a new global leader in human health with new Life Solutions, manufactured and developed from our core technology: Molecule Vitalization. Molecule Vitalization can turn existing molecules into new treatments with new promise.
Our values are human. And our minds are open. Changing the world isn't just a dream, it's our mandate. And we're here to prove it.

www.bachem.com

Caprion, Programme Partner

Caprion provides GCP/GLP/GCLP immune monitoring and proteomics services to 50+ major companies in the pharmaceutical and biotechnology industry for their vaccine and immunotherapy programs. Caprion's immune monitoring business unit, ImmuneCarta®, offers proprietary multiparametric flow cytometry for functional analyses of innate and adaptive immune responses. ImmuneCarta offers a complete menu of off-the-shelf and customizable assays to characterize and monitor immune response during discovery, pre-clinical, and Phase I—III clinical development. Caprion's proteomics division, ProteoCartaTM, offers gel-free, label-free mass spectrometry for comprehensive, quantitative and robust comparative measurement of proteins across large sets of biological samples for discovery and validation of protein biomarkers..

www.caprion.com

Almac, Exhibitor

Almac has been supplying peptides to the research community and for clinical trials for over 20 years. The field of personalized cancer vaccines requires a new manufacturing paradigm to ensure high throughput manufacture of multiple neoantigens in an appropriate timescale to the required quality and regulatory standards. Almac has created a unique offering to meet all of those demands, which can be tailored to meet specific client needs.

www.almacgroup.com/api-chemical-development

BECOME A PARTNER

Jennifer Mackay
Commercial Manager
T: +44 203 141 8700
E: sponsor@hansonwade.com

READY TO REGISTER?

3 EASY WAYS TO BOOK

www.neoantigen-europe.com/register

Tel: +44 203 141 8700

Email: register@hansonwade.com

BENEFITS OF ATTENDING

1. Revolutionising Neoantigen Identification & Prediction: Learn about the most cutting-edge techniques being used to select the right neoantigens
2. Guaranteeing Immunogenicity: Update your current strategies to ensure your neoantigens have the desired immune response
3. Manufacturing Personalised Cancer Vaccines: Develop a manufacturing strategy to efficiently upscale the production of individualised immunotherapies

Team Discounts*

- **10% discount – 3 delegates**
- **15% discount – 4 delegates**
- **20% discount – 5 or more delegates**

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Contact: register@hansonwade.com

SECURE YOUR PLACE

INDUSTRY/DRUG DEVELOPERS		
	Register & Pay by March 23rd	**Standard**
Conference + 2 Workshops	€2997 + VAT **(save €400)**	€3197 + VAT (save €200)
Conference + 1 Workshops	€2498+ VAT **(save €300)**	€2698 + VAT (save €100)
Conference Only	€1999 + VAT **(save €200)**	€2199 + VAT
1 Workshop	€599 + VAT	

***Academics are entitled to 30% off the drug developer price. Use code "ACA" when registering online.**

SOLUTION/SERVICE PROVIDER PRICING		
	Register & Pay by March 23rd	**Standard**
Conference + 2 Workshops	€4297 + VAT **(save €300)**	€4397 + VAT (save €200)
Conference + 1 Workshops	€3698 + VAT **(save €200)**	€3798 + VAT (save €100)
Conference Only	€3099 + VAT **(save €100)**	€3199 + VAT
1 Workshop	€699 + VAT	

VAT will be charged at 21%

VENUE

Postillion Convention Centre Amsterdam
Paul van Vlissingenstraat 8
1096 BK, Amsterdam
The Netherlands

For further information or assistance, please visit: www.postillionhotels.com/en-gb/conferenties-events/amsterdam

Code: 9558